A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

December 31, 2002

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
HIV Infections
Interventions
DRUG

Atazanavir (immediate switch)

Capsules, Oral, 400mg, Once daily, 48 weeks.

DRUG

Atazanavir (Week 24 switch)

Capsules, Oral, 400mg, Once daily, 48 weeks.

Trial Locations (19)

Unknown

Local Institution, Phoenix

Local Institution, West Hollywood

Local Institution, Washington D.C.

Local Institution, Altamonte Springs

Local Institution, Fort Lauderdale

Local Institution, Miami

Local Institution, Tampa

Local Institution, Boston

Local Institution, Minneapolis

Local Institution, St Louis

Local Institution, East Orange

Local Institution, New York

Local Institution, Huntersville

Local Institution, Cleveland

Local Institution, Oklahoma City

Local Institution, Philadelphia

Local Institution, Columbia

Local Institution, Fort Worth

Local Institution, Houston

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY